{
  "docId": "019de075-3cec-7700-94db-076a5ce30d84",
  "docSlug": "8c2d629a90974743be7d15f16a23e50f",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 42,
  "pageCount": 56,
  "prevPage": 41,
  "nextPage": 43,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a timeline-based process diagram to illustrate the clinical trial strategy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-3cec-7700-94db-076a5ce30d84/42",
  "deckHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84",
  "deckJsonHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84.json",
  "deckAnchorHref": "/decks/019de075-3cec-7700-94db-076a5ce30d84#slide-42",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.96,
        "x": 0.02,
        "y": 0.18
      },
      "kind": "framework",
      "text": "Phase 1 to Phase 3 clinical trial progression",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "471019a6-16e2-461b-b917-511486cfcf30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.58,
        "x": 0.4,
        "y": 0.8
      },
      "kind": "paragraph",
      "text": "Comparable development strategy to be pursued with SPY002 (TL1A) combinations",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce6c78e1-d760-44d4-b335-c34cbbe0762d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.02,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "Preliminary; pending regulatory feedback",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39ada85e-c3dd-4c93-9a7d-1a9c34d92b94",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.75,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "We plan to rapidly advance combination programs in parallel with monotherapies in Phase 2",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "509f66a4-a000-4702-a3dc-d14ab252449d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "b338290d-bfc3-46b0-bf2e-335ffa29eead",
      "evidence": "The slide depicts a sequential progression of clinical trial phases over time.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 44,
      "from": 31,
      "beatId": "5c590fe3-bdd5-4bd1-85d4-420b5f2a4608",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence",
      "beatSlug": "evidence",
      "evidence": "The document provides evidence to support the company's solution",
      "position": 4,
      "confidence": 0.9,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}